HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Sarcoma (Soft Tissue Sarcoma)

A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.

Also Known As:

Soft Tissue Sarcoma; Sarcomas; Soft Tissue Sarcomas; Spindle Cell Sarcoma; Epithelioid Sarcoma; Epithelioid Sarcomas; Sarcomas, Epithelioid; Sarcomas, Soft Tissue; Sarcomas, Spindle Cell; Spindle Cell Sarcomas; Sarcoma, Epithelioid; Sarcoma, Soft Tissue; Sarcoma, Spindle Cell

Networked: 14738 relevant articles (680 outcomes, 1946 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Sarcoma (Soft Tissue Sarcoma)
3.	Melanoma (Melanoma, Malignant)
4.	Neoplasm Metastasis (Metastasis)
5.	Carcinoma (Carcinomatosis)

Experts

1.	Blay, Jean-Yves: 68 articles (12/2015 - 01/2003)
2.	Le Cesne, Axel: 43 articles (12/2015 - 08/2005)
3.	Maki, Robert G: 40 articles (06/2015 - 08/2002)
4.	Pollock, Raphael E: 35 articles (10/2015 - 04/2002)
5.	Ray-Coquard, Isabelle: 35 articles (04/2015 - 01/2004)
6.	Picci, Piero: 34 articles (11/2015 - 12/2002)
7.	O'Sullivan, Brian: 33 articles (11/2015 - 05/2002)
8.	Le Cesne, A: 33 articles (11/2015 - 07/2000)
9.	Houghton, Peter J: 32 articles (11/2015 - 08/2007)
10.	Benjamin, Robert S: 32 articles (04/2015 - 09/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Sarcoma:

1.	Doxorubicin (Adriamycin)FDA LinkGeneric 12/01/2002 - "A 78-year-old man presented with high-grade myofibroblastic sarcoma 13 years after curatively intended pion irradiation of the prostate with 30 Gy. He was treated with liposomal doxorubicin 40 mg/m(2) every 4-6 weeks up to now with a total dose of 800 mg. Partial remission has been achieved after 17 months of treatment with liposomal doxorubicin. " 01/01/2013 - "Doxorubicin, first reported to have activity in sarcomas 40 years ago, remains the generalizable first-line treatment of choice for many subtypes, with no other drug or combination having shown an overall-survival advantage. " 04/01/1981 - "Radionuclide cineangiography was used to evaluate 32 patients who sustained long-term remission of soft tissue sarcoma after adjuvant therapy with a cumulative doxorubicin dose from 480 to 550 mg/m body surface area. " 03/01/2012 - "The results of this trial are very useful for estimating the outcomes of first-line therapy of sarcoma patients treated with standard doxorubicin." 03/01/2012 - "This study evaluated the safety and efficacy of doxorubicin ± conatumumab as first-line systemic therapy for metastatic or locally advanced/unresectable soft-tissue sarcoma. "
2.	Ifosfamide FDA LinkGeneric 11/01/1998 - "The aim of the present study was to assess the activity of ifosfamide with a new schedule for patients with advanced soft tissue sarcoma failing to achieve remission or relapsing following anthracycline-containing regimens; it was attempted to individualize dosages and prevent excessive toxicity. " 08/01/2000 - "Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma." 01/01/2015 - "This phase II trial was performed to evaluate the activity and the safety of NPLD and ifosfamide combination in patients with metastatic soft tissue sarcoma. " 07/01/2011 - "The aim of present study was to determine the frequency and severity of ifosfamide nephropathy in patients with various types of sarcoma. " 03/01/2006 - "Phase I trial and pharmacokinetic analysis of ifosfamide in cats with sarcomas."
3.	trabectedin (ecteinascidin 743)IBA 06/01/2012 - "Previous studies in sarcoma found that a composite gene signature, including high expression of nucleotide excision repair (NER) genes (XPG and/or ERCC1) and low expression of homologous recombination repair (HR) genes (BRCA1), identifies a highly sensitive population of patients with significantly improved outcome to trabectedin. " 01/01/2013 - "The present paper on a promising treatment with neoadjuvant trabectedin of patients with high-grade pleomorphic sarcoma might suggest that such treatment approach may provide a greater chance of cure and survival of such patients." 01/01/2013 - "This polymorphism was previously shown to be associated with better outcome in soft tissue sarcoma patients treated with trabectedin. " 08/01/2014 - "Trabectedin may be especially effective against translocation-related sarcomas." 01/01/2012 - "Trabectedin, a new antitumor compound originally derived from a marine tunicate, is clinically effective in soft tissue sarcoma. "
4.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/01/2009 - "The objective of the present study was to confirm these data on a larger sample size of locally advanced or recurrent extremity soft tissue sarcomas with low-dose TNF-alpha. " 08/01/1992 - "In this study, we investigated the effect of tumor necrosis factor-alpha (TNF alpha) on the generation and function of IVS cells utilized in adoptive immunotherapy of the murine MCA 106 sarcoma. " 04/15/1989 - "Early metabolic response to tumor necrosis factor in mouse sarcoma: a phosphorus-31 nuclear magnetic resonance study." 03/01/2015 - "Based on this knowledge, we conceived to use modified MSC to deliver tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) targeting different sarcoma histotypes. " 09/03/2010 - "NFkappaB activity is very low in unstimulated Ewing sarcoma cells, but can be induced in response to tumor necrosis factor (TNF). "
5.	Melphalan (Alkeran)FDA LinkGeneric 03/15/1997 - "The combination of high dose rTNF-alpha and melphalan given via ILP appears to be effective in patients with advanced soft tissue sarcoma confined to the limb, achieving a high response rate and limb preservation." 05/01/2001 - "HILP with melphalan is a safe and effective treatment option for selected patients with locally advanced and unresectable extremity sarcomas. " 03/15/1997 - "The purpose of the current study was to assess the role of rTNF-alpha and melphalan administered via ILP in patients with soft tissue sarcoma. " 02/15/2015 - "The addition of oncolytic vaccinia virus to existing TNF-α/melphalan-based ILP strategies results in survival advantage in an immunocompetent rat model of advanced extremity sarcoma. " 02/15/2015 - "An orthotopic model of advanced extremity sarcoma was used to evaluate survival of animals after ILP with combinations of TNF-α, melphalan and GLV-1h68. "
6.	Cyclophosphamide (Cytoxan)FDA LinkGeneric 07/01/2007 - "Low dose radiation increased the therapeutic efficacy of cyclophosphamide on S(180) sarcoma bearing mice." 05/01/2011 - "Experimental study of extracorporeal exposure of autoblood to red monochromatic photodiode radiation for improving antitumor efficiency of cyclophosphamide injected with autoblood was carried out on the model of sarcoma 45 cells ectopically transplanted to the lungs. " 12/01/2003 - "This article reports the experiment studies on treating the S-180 sarcomas of KM mice with high-intensity electric pulse and antitumor drug (cyclophosphamide). " 11/01/1987 - "In vitro studies revealed that Kupffer cell tumoricidal activity against sarcoma was increased (p less than 0.05) following glucan and cyclophosphamide. " 04/01/1963 - "Clinical trials with cyclophosphamide in children with soft tissue sarcoma."
7.	Cisplatin (Platino)FDA LinkGeneric 05/01/2015 - "The combination of ombrabulin and cisplatin significantly improved progression-free survival; however, it did not show a sufficient clinical benefit in patients with advanced soft-tissue sarcomas to support its use as a therapeutic option. " 05/01/2015 - "In this phase 3 trial, we aimed to assess the efficacy and safety of ombrabulin plus cisplatin compared with placebo plus cisplatin in patients with advanced soft-tissue sarcomas. " 12/01/2006 - "The aim of our study was to evaluate feasibility and therapeutic potential of electrogene therapy with p53 alone or combined with electrochemotherapy using cisplatin on two murine sarcomas with different p53 status. " 07/01/2005 - "The objectives of this study were to investigate the pharmacokinetics of cisplatin (CDDP) and the thermal dose, toxicity, and feasibility of hyperthermic isolated regional perfusion (HIRP) with CDDP for bone and soft-tissue sarcomas of the lower limb. " 07/01/1986 - "The M5076 sarcoma was used to evaluate the antitumor activities of several analogs of Platinol presently undergoing clinical trials. "
8.	gemcitabine FDA Link 10/15/2015 - "This study was performed to determine the maximum tolerated dose (MTD) of gemcitabine given concurrently with preoperative, fixed-dose external-beam radiation therapy (EBRT) for patients with resectable, high-risk extremity and trunk soft tissue sarcoma (STS). " 10/15/2015 - "Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma." 12/01/2008 - "Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study." 05/01/2007 - "This study contributed to data that have supported the administration of fixed-dose rate gemcitabine-based drug regimens in soft-tissue sarcomas." 05/01/2006 - "An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma."
9.	pazopanibIBA 01/01/2013 - "The randomized, double-blind, placebo-controlled, Phase III PALETTE (pazopanib for metastatic soft-tissue sarcoma) study demonstrated improved progression-free survival in patients receiving pazopanib compared with placebo. " 11/12/2012 - "The clinical efficacy of oral pazopanib in patients with metastatic soft tissue sarcoma (STS) was demonstrated in a randomized, double-blind, placebo-controlled, phase III trial (PALETTE), generally confirming the findings of an earlier, noncomparative phase II study. " 01/01/2015 - "Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series." 09/01/2015 - "Health-related quality of life (HRQoL) was an exploratory endpoint in the PALETTE trial, a global, double-blind, randomized, phase 3 trial of pazopanib 800 mg versus placebo as second-line or later treatment for patients with advanced soft tissue sarcoma (N = 369). " 05/01/2015 - "Pazopanib is tolerable to soft tissue sarcoma patients ineligible for the PALETTE study and some of them respond to pazopanib, but the prognoses of patients ineligible for the PALETTE study might be worse than those of PALETTE-eligible patients. "
10.	AntigensIBA 08/06/2013 - "In this model, we evaluated the therapeutic efficacy of T cells redirected against the Ewing sarcoma-associated antigen GD2 by chimeric receptor engineering. " 08/18/2007 - "To compare the efficacy of different immunotherapeutic strategies of loading dendritic cells (DCs) with the antigen of the Ewing sarcoma in vitro and in vivo. " 01/01/2012 - "Another was a phase II trial using neo-adjuvant apoptosis-inducing EBRT plus intra-tumoral DC in soft tissue sarcoma, to test if this would increase immune activity toward soft tissue sarcoma associated antigens. " 01/01/2009 - "In this study we present the models of preventive and therapeutic vaccination of sarcoma-bearing rats with dendritic cells that present tumour antigens from killed tumour cells. " 11/01/1995 - "Our study examines the prognostic value of these cell-cycle antigens in soft tissue sarcoma (STS). "

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 09/01/2014 - "There are limited data to guide the best treatment for radiation-associated sarcoma, therefore, the standard chemotherapy options are reasonable choices. " 10/01/2013 - "The improvement in outcome for patients with localized and metastatic Ewing sarcoma since the development of cytotoxic chemotherapy remains one of the most profound advances in oncology and one of the proudest achievements of sarcoma researchers. " 03/01/2010 - "Outcomes for patients with bone sarcomas have improved dramatically over the past 40 years, and most bone sarcomas today are treated with surgery and chemotherapy. " 02/01/2009 - "On the other hand, the efficacy of chemotherapy is unclear in most of the non-round cell sarcomas, e. " 10/01/2008 - "Our limited - albeit the most extensive - experience with cardiac sarcomas has helped improve survival compared with chemotherapy alone. "
2.	Radiotherapy 01/01/1998 - "This study indicates that although postoperative external-beam radiotherapy is highly effective in preventing LRs, selected patients with extremity soft tissue sarcoma who have a low risk of LR may not require adjuvant XRT after limb-sparing surgery (LSS)." 08/01/1996 - "The best treatment for thyroid sarcomas and SCC of the thyroid is early diagnosis and aggressive surgery combined with radiotherapy." 02/01/2011 - "The gold standard for the treatment of primary, resectable, high-grade soft tissue sarcomas is complete surgical removal followed by radiotherapy. " 07/10/2015 - "The significant reduction of late toxicities in patients with extremity STS who were treated with preoperative IGRT and absence of marginal-field recurrences suggest that the target volumes used in the Radiation Therapy Oncology Group RTOG-0630 (A Phase II Trial of Image-Guided Preoperative Radiotherapy for Primary Soft Tissue Sarcomas of the Extremity) study are appropriate for preoperative IGRT for extremity STS." 09/01/2015 - "Radiotherapy, regardless of the timing, is associated with improved survival in high-risk sarcoma."
3.	Adjuvant Chemotherapy 11/01/2000 - "Both studies confirm the advantage of adjuvant chemotherapy in disease-free and overall surivall in very select groups of high-grade sarcomas of the extremities." 06/01/1998 - "Adjuvant chemotherapy has significantly improved the prognosis of patients with bone sarcomas. " 04/15/1986 - "These results suggest that primary adjuvant chemotherapy is beneficial in patients with Stage I uterine sarcomas." 03/15/1985 - "Since 1977, 31 patients were entered in a randomized, prospective study testing the efficacy of adjuvant chemotherapy after aggressive local treatment of high-grade sarcomas of the head, neck, breast, and trunk (excluding retroperitoneal sarcomas). " 09/01/1984 - "Prospective randomized trials demonstrating the efficacy of adjuvant chemotherapy in adult patients with soft tissue sarcomas."
4.	Brachytherapy 02/01/2006 - "Brachytherapy used as an isolated treatment combined with surgery has proven to be effective in high-grade sarcomas, compared to surgery alone, in a unique randomized trial. " 02/01/2003 - "Primary exclusive brachytherapy has been used and is effective and safe in high grade sarcomas (randomized trial of MSKCC). " 01/01/2015 - "To assess the toxicity and efficacy of salvage wide resection (SWR) with intraoperative electron beam radiation therapy (IOERT) or perioperative high-dose-rate brachytherapy (PHDRB) in previously unirradiated patients (PUP) vs. previously irradiated patients (PIP) with isolated local recurrence of soft tissue sarcomas (STS) of the extremities and the superficial trunk. " 01/01/2013 - "The Ablative surgery, MOulage brachytherapy and REconstruction) (AMORE) protocol developed in the Academic Medical Center of Amsterdam has been used successfully to treat sarcomas. " 09/01/1997 - "Conventional low-dose-rate (LDR) brachytherapy is effective in treating childhood sarcomas, but often not practical (due to the associated radiation hazards) in the young children who require continuous observation and sedation. "
5.	Combination Drug Therapy (Combination Chemotherapy) 01/01/1989 - "The authors describe the case of a 16 year old boy with primary hepatic sarcoma showing a rhabdomyoblastic differentiation, who is in complete remission two years after total surgical resection and polychemotherapy." 07/01/1994 - "Disease-free survival for patients with small sarcomas of bone has been impressively improved with the use of intensive combination chemotherapy and safe local control with surgery or radiation. " 10/01/2011 - "In this non-randomised multicentre phase 2 study, patients were included if they had progressive or high-grade soft-tissue sarcoma and had received no more than one previous combination chemotherapy or up to two single drugs for advanced disease. " 06/01/2010 - "We describe herein the current concepts tested in clinical trials dedicated to patients with metastatic soft tissue sarcomas: identify predictive factors under anthracyclin-based regimens, identify patients beneficing from polychemotherapy, benefit of maintenance treatment, use of non-progression rate rather than response rate for selecting new drugs, histology-tailored or biological target-tailored second-line treatment." 08/01/1995 - "This article summarizes the results of single agent and combination chemotherapy trials for soft tissue sarcomas."